8-K
Abbott Laboratories (ABT)
| Common Shares, Without Par Value | ABT |
|---|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) ofthe
Securities Exchange Act of 1934
April 24, 2020
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in charter)
| Illinois | 1-2189 | 36-0698440 |
|---|---|---|
| (State or other Jurisdiction | (Commission File Number) | (IRS Employer |
| of Incorporation) | Identification No.) |
100 Abbott Park Road
Abbott Park,Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code:
(224) 667-6100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading<br><br> <br>Symbol(s) | Name of Each Exchange on<br><br> <br>Which Registered |
|---|---|---|
| Common Shares, Without Par Value | ABT | New<br>York Stock Exchange<br><br><br><br>Chicago<br>Stock Exchange, Inc. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
I****tem5.07 — Submission of Matters to a Vote of Security Holders.
Abbott held its Annual Meeting of Shareholders on April 24, 2020. The following is a summary of the matters voted on at that meeting.
| (1) | The shareholders elected Abbott’s entire Board of Directors. The persons elected to Abbott’s Board of Directors<br>and the number of shares cast for, the number of shares withheld, and the number of broker non-votes, with respect to each of these<br>persons, were as follows: | ||||||
|---|---|---|---|---|---|---|---|
| Name | Votes For | Votes Withheld | Broker Non-Votes | ||||
| --- | --- | --- | --- | --- | --- | --- | |
| Robert J. Alpern, M.D. | 1,339,883,794 | 17,727,527 | 205,521,308 | ||||
| Roxanne S. Austin | 1,288,595,809 | 69,015,512 | 205,521,308 | ||||
| Sally E. Blount, Ph.D. | 1,353,893,667 | 3,717,654 | 205,521,308 | ||||
| Robert B. Ford | 1,343,514,772 | 14,096,550 | 205,521,308 | ||||
| Michelle A. Kumbier | 1,343,669,496 | 13,941,825 | 205,521,308 | ||||
| Edward M. Liddy | 1,333,732,689 | 23,878,632 | 205,521,308 | ||||
| Darren W. McDew | 1,352,315,607 | 5,295,714 | 205,521,308 | ||||
| Nancy McKinstry | 1,067,064,716 | 290,546,605 | 205,521,308 | ||||
| Phebe N. Novakovic | 1,341,182,943 | 16,428,379 | 205,521,308 | ||||
| William A. Osborn | 1,323,132,704 | 34,478,618 | 205,521,308 | ||||
| Daniel J. Starks | 1,340,794,056 | 16,817,265 | 205,521,308 | ||||
| John G. Stratton | 1,353,108,028 | 4,503,294 | 205,521,308 | ||||
| Glenn F. Tilton | 1,296,859,378 | 60,751,943 | 205,521,308 | ||||
| Miles D. White | 1,321,600,922 | 36,010,399 | 205,521,308 | ||||
| (2) | The shareholders ratified the appointment of Ernst & Young LLP as Abbott’s auditors. The number of shares cast in<br>favor of the ratification of Ernst & Young LLP, the number against, the number abstaining, and the number of broker non-votes<br>were as follows: | ||||||
| --- | --- | ||||||
| For | Against | Abstain | Broker Non-Votes | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1,550,970,892 | 9,518,284 | 2,643,453 | 0 | ||||
| (3) | The shareholders voted to approve the compensation of Abbott’s named executive officers listed in the proxy statement<br>for the 2020 annual meeting, with 92.01 percent of the votes cast voting “For” the proposal. The shareholder vote is<br>advisory and non-binding. The number of shares cast in favor of approval, the number against, the number abstaining, and the number<br>of broker non-votes were as follows: | ||||||
| --- | --- | ||||||
| For | Against | Abstain | Broker Non-Votes | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1,249,119,989 | 100,298,672 | 8,192,660 | 205,521,308 | ||||
| (4) | The shareholders rejected a shareholder proposal that Abbott’s Board of Directors prepare a report, to be updated annually,<br>disclosing Abbott’s lobbying policies, procedures, and expenditures, with 19.68 percent of the votes cast voting “For”<br>the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the<br>number of broker non-votes were as follows: | ||||||
| --- | --- | ||||||
| For | Against | Abstain | Broker Non-Votes | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 267,208,881 | 1,082,456,479 | 7,945,960 | 205,521,308 | ||||
| (5) | The shareholders rejected a shareholder proposal requesting that Abbott provide certain proxy disclosure regarding adjustments<br>to GAAP financial performance metrics, with 30.76 percent of the votes cast voting “For” the proposal. The number of<br>shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes<br>were as follows: | ||||||
| --- | --- | ||||||
| For | Against | Abstain | Broker Non-Votes | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 417,543,155 | 931,644,755 | 8,423,410 | 205,521,308 | ||||
| (6) | The shareholders rejected a shareholder proposal requesting that any Board approved By-Law amendment be subject to a non-binding<br>shareholder vote, with 2.38 percent of the votes cast voting “For” the proposal. The number of shares cast in favor<br>of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows: | ||||||
| --- | --- | ||||||
| For | Against | Abstain | Broker Non-Votes | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 32,263,098 | 1,317,026,280 | 8,321,942 | 205,521,308 | ||||
| (7) | The shareholders passed a shareholder proposal regarding simple majority vote, with 84.48 percent of the votes cast voting<br>“For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number<br>abstaining, and the number of broker non-votes were as follows: | ||||||
| --- | --- | ||||||
| For | Against | Abstain | Broker Non-Votes | ||||
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1,146,927,037 | 204,066,841 | 6,617,443 | 205,521,308 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ABBOTT LABORATORIES | ||
|---|---|---|
| Date: April 28, 2020 | By: | /s/ Robert E. Funck, Jr. |
| Robert E. Funck, Jr. | ||
| Executive Vice President, Finance | ||
| and Chief Financial Officer |